Gapping up
In reaction to earnings/guidance:
- TWLO +9.3% (guides Q3 revs above consensus), NUS +7.7% (guides Q3 revenue well above consensus), .
Other news:
- NNOX +26.2% (to demonstrate Nanox.ARC system live at RSNA 2020)
- CFFN +9.9% (to join S&P SmallCap 600)
- RNST +9.7% (to join S&P SmallCap 600)
- MTSC +8.9% (awarded two contracts)
- AGO +8.9% (to join S&P SmallCap 600)
- IVZ +7.9% (Trian (Nelson Peltz) confirms 9.9% active stake in Invesco)
- HGEN +7.8% (announced updates on its lenzilumab in COVID-19 development program, including written guidance received from the FDA following a Type B meeting to obtain feedback on plans for an EUA)
- IBIO +6.8% (enters into a Master Services Agreement with Boston-based Safi Biosolutions, Inc. to evaluate iBio's FastPharming System for the expression of key proteins to be used in the bioprocessing of Safi blood cell therapy products)
- TNAV +4.9% (confirms non-binding "go private" proposal to acquire all of the outstanding shares for $4.32 per share)
- OZK +3.1% (increases dividend slightly)
- NBEV +2.3% (amends merger agreement with ARIIX)
- PSN +1.1% (awarded $50.6 mln contract from US Air Force)
- NTST +1.1% (provides Q3 business update)
- BLUE +1.1% (receives EMA acceptance of MAA for elivaldogene autotemcel)
Analyst comments:
- UBSI +1.7% (upgraded to Outperform from Mkt Perform at Keefe Bruyette)
- IMGN +1.6% (upgraded to Buy from Neutral at Guggenheim)